tx 3301 has been researched along with aspirin in 61 studies
Studies (tx 3301) | Trials (tx 3301) | Recent Studies (post-2010) (tx 3301) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
---|---|---|---|---|---|
69 | 15 | 16 | 48,947 | 6,817 | 13,778 |
Protein | Taxonomy | tx 3301 (IC50) | aspirin (IC50) |
---|---|---|---|
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
Integrin beta-3 | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
Integrin alpha-IIb | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.64) | 18.7374 |
1990's | 1 (1.64) | 18.2507 |
2000's | 43 (70.49) | 29.6817 |
2010's | 15 (24.59) | 24.3611 |
2020's | 1 (1.64) | 2.80 |
Authors | Studies |
---|---|
Maurer, HJ | 1 |
Annemans, L; Dresse, A; Kurz, X | 1 |
Cohen, SN | 1 |
Bergmann, SR | 2 |
Hilleman, DE; Lenz, TL | 1 |
Scheen, AJ | 1 |
Kipp, A | 1 |
Hansen, DB | 1 |
Anderson, JD; Littmann, L; Monroe, MH | 1 |
Malinin, AI; Sane, DC; Serebruany, VL | 1 |
Lenz, T; Wilson, A | 1 |
Haberl, R | 1 |
Redman, AR; Ryan, GJ | 1 |
Fisher, M; Moonis, M | 1 |
Atar, D; Ferguson, JJ; Hanley, DF; Serebruany, VL | 1 |
Marissal, JP; Selke, B | 1 |
Lindberg, M | 1 |
Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A | 1 |
Gray, CS; Morton, JA; Newton, J | 1 |
Beck, GJ; Dember, LM; Depner, TA; Dixon, BS; Feldman, HI; Gassman, JJ; Greene, T; Himmelfarb, J; Hunsicker, LG; Kaufman, JS; Lawson, JH; Meyers, CM; Middleton, JP; Radeva, M; Schwab, SJ; Whiting, JF | 1 |
Schuler, G | 1 |
Horton, HL | 1 |
Byrne, MF; Conroy, R; Cox, D; Dooley, M; Fitzgerald, DJ; Maree, AO | 1 |
Ackerstaff, RG; de Borst, GJ; de Vries, JP; Hilgevoord, AA; Moll, FL; van de Pavoordt, HD; van der Mee, M | 1 |
Macdonald, S | 1 |
Sedrakyan, A; Shih, C | 1 |
Hanley, DF; Malinin, AI; Serebruany, VL | 1 |
Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL | 1 |
Diener, HC; Sacco, R; Yusuf, S | 1 |
Hoover, PL; Mold, JW | 1 |
Barabás, JB; Horváth, C; Joób-Fancsaly, A; Kalmár, G; Koppány, F | 1 |
Jao, T; Jeng, JS; Tsai, TH | 1 |
Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH | 1 |
Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V | 1 |
Schwab, S | 1 |
Meyer, D | 1 |
Dengler, R; Diener, HC; Eschenfelder, CC; Grond, M; Haberl, R; Kastrup, A; Leonard, J; Machnig, T; Schumacher, H; Schwartz, A; Weissenborn, K | 1 |
Crown, N; Mysak, T | 1 |
Bédard, M; Dubois, S; Gibbons, C; Hargadon, J; Joy, K | 1 |
Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V | 1 |
Allon, M; Beck, GJ; Braden, GL; Cotton, JR; Davidson, IJ; Delmez, JA; Dember, LM; Dixon, BS; Feldman, HI; Greenberg, A; Greene, T; Himmelfarb, J; Hu, B; Ikizler, TA; Kusek, JW; Lawson, JH; Radeva, MK; Vazquez, MA | 1 |
Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T | 1 |
Bath, P; Hogg, C; Pocock, S; Tracy, M | 1 |
Collins, R; Coughlan, T; Cox, D; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tobin, WO | 1 |
Brickl, R; Ehrlich, J; Eisert, W; Offman, E; Schobelock, MJ; VanderMaelen, CP | 1 |
Bath, PM; Cotton, D; Diener, HC; Sacco, RL; Sha, N; Weber, R; Weimar, C | 1 |
Alasty, P; Hamishehkar, H; Monajjemzadeh, F; Valizadeh, H | 1 |
Abbott, KC; Himmelfarb, J; Little, DJ; Lowe, SR; Nee, R; Parker, AL; Yuan, CM | 1 |
Asher, CR; Buitrago, I; Wolinsky, D | 1 |
Fletcher, J; Gruen, R; Koh, TL; Ong, WL; Royce, P | 1 |
Chang, TY; Fan, PY; Hsieh, MY; Kuo, CF; Lee, CC; Li, IJ; Liu, SH; Tian, YC; Tu, KH; Weng, CH; Wu, HH; Yang, CW | 1 |
Bdiiwi, S; Boison, D; Boktor, H; Castro, D; Dadario, NB; Finkle, D; Greenberg, P; Khandelwal, P; Koziol, J; Kyi, HH; Libutti, SK; Liu, J; Ly, K; Malhotra, R; Maninderpal, K; Nanda, A; Nipun, S; Patel, S; Patrawalla, A; Singla, A; Sonig, A; Subanna, S; Sutherland, A; Xie, Y; Yan, R | 1 |
9 review(s) available for tx 3301 and aspirin
Article | Year |
---|---|
Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Stroke | 2000 |
[Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Primary Prevention; Stroke; Treatment Outcome | 2000 |
Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2003 |
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Stroke; Ticlopidine | 2004 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticlopidine | 2003 |
[Current issues of anticoagulation therapy in the course of dental treatment and oral surgery].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dental Care; Dipyridamole; Drug Administration Schedule; Drug Combinations; Humans; Oral Surgical Procedures; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2009 |
Antiplatelets and stroke outcomes: state of the science.
Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Combinations; Evidence-Based Practice; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Risk Reduction Behavior; Safety; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2009 |
Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Meta-Analysis as Topic; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke | 2010 |
15 trial(s) available for tx 3301 and aspirin
Article | Year |
---|---|
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?
Topics: Adenosine Diphosphate; Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Capsules; Dipyridamole; Dose-Response Relationship, Drug; Drug Combinations; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Stroke; Time Factors | 2003 |
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Dipyridamole; Drug Combinations; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Endothelial Cell Adhesion Molecule-1; Platelet Function Tests; Platelet Membrane Glycoprotein IIb; Platelet Membrane Glycoproteins; Stroke; Tetraspanin 24; Time Factors; Treatment Outcome | 2004 |
Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
Topics: Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Body Weight; Cross-Over Studies; Dipyridamole; Dose-Response Relationship, Drug; Drug Combinations; Humans; Logistic Models; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Reference Values; Tablets, Enteric-Coated; Therapeutic Equivalency; Thromboxane B2; Treatment Outcome | 2006 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyridamole; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Endarterectomy, Carotid; Female; Hemorrhage; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pilot Projects; Platelet Aggregation Inhibitors; Postoperative Care; Prospective Studies; Stroke; Ticlopidine; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2007 |
Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan).
Topics: Adult; Antigens, CD; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Blood Platelets; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Female; Flow Cytometry; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoproteins; Reference Values; Research Design; Time Factors | 2008 |
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
Topics: Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Clopidogrel; Diabetes Mellitus, Type 2; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Single-Blind Method; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Erythrocytes; Female; Humans; Ischemia; Leukocytes; Male; Middle Aged; Risk Factors; Spectrometry, Fluorescence; Stroke; Time Factors; Treatment Outcome | 2009 |
Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Double-Blind Method; Drug Combinations; Female; Germany; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Time Factors | 2010 |
Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Atherosclerosis; Biomarkers; Case-Control Studies; Dipyridamole; Double-Blind Method; Drug Combinations; Female; Humans; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase Type III; Pharmacokinetics; Platelet Aggregation Inhibitors; Stroke | 2011 |
Use of aspirin associates with longer primary patency of hemodialysis grafts.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Chronic Disease; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Diseases; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Renal Dialysis; Thrombosis; Treatment Outcome; Vascular Patency | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Treatment Outcome | 2011 |
Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Topics: Adolescent; Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Cross-Over Studies; Dipyridamole; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Young Adult | 2013 |
Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Topics: Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2013 |
Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.
Topics: Adult; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Cost-Benefit Analysis; Dipyridamole; Double-Blind Method; Drug Combinations; Graft Occlusion, Vascular; Humans; Monte Carlo Method; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Renal Dialysis | 2014 |
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.
Topics: Antiviral Agents; Aspirin; Aspirin, Dipyridamole Drug Combination; COVID-19; Female; Humans; SARS-CoV-2; Treatment Outcome | 2023 |
37 other study(ies) available for tx 3301 and aspirin
Article | Year |
---|---|
[Coagulation disorder following angiography with a nonionic tri-iodized contrast medium? Effect due to contrast medium or to heparin?].
Topics: Aortography; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Coagulation Disorders; Blood Coagulation Tests; Contrast Media; Dipyridamole; Drug Combinations; Heparin; Humans; Iopamidol; Iothalamic Acid; Male; Middle Aged | 1985 |
[An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Belgium; Cerebrovascular Disorders; Cost-Benefit Analysis; Costs and Cost Analysis; Delayed-Action Preparations; Dipyridamole; Disease-Free Survival; Drug Combinations; Drug Costs; Economics, Pharmaceutical; Follow-Up Studies; Humans; Markov Chains; Placebos; Platelet Aggregation Inhibitors; Recurrence; Sensitivity and Specificity; Social Security | 1998 |
Aggrenox: a combination of antiplatelet drugs for stroke prevention.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Dipyridamole; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Fees, Pharmaceutical; Humans; Platelet Aggregation Inhibitors; Stroke | 2000 |
Dipyridamole plus aspirin in cerebrovascular disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Research Design; Risk Assessment; Scientific Misconduct; Stroke; Treatment Outcome | 2000 |
Alert to physicians: possible interaction of aggrenox and adenosine.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Vasodilator Agents | 2000 |
Aggrenox and stress testing.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemia; Platelet Aggregation Inhibitors; Stroke; Vasodilator Agents | 2001 |
Second stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Chemoprevention; Dipyridamole; Drug Approval; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; United States; United States Food and Drug Administration | 2000 |
Antithrombotic drugs for secondary stroke prophylaxis--a comment.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2001 |
Adenosine and Aggrenox: a hazardous combination.
Topics: Adenosine; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Bradycardia; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Female; Heart; Humans; Radionuclide Imaging | 2002 |
[Secondary prevention after stroke. 2 platelet inhibitors are better than one].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Treatment Outcome | 2002 |
[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Telmisartan; Ticlopidine | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Controlled Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Placebos; Platelet Aggregation Inhibitors; Recurrence; Risk; Stroke; Telmisartan; Ticlopidine; Time Factors | 2003 |
[ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke | 2003 |
[Secondary prevention after stroke. Doubled performs better].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Placebos; Platelet Aggregation Inhibitors; Stroke | 2003 |
[After stroke or TIA. Double protection by second platelet inhibitor].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Ischemic Attack, Transient; Placebos; Practice Guidelines as Topic; Risk; Stroke | 2003 |
Noncompliance in antiplatelet trials: the AGATE trial perspective.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Stroke; Treatment Refusal | 2004 |
Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
Topics: Adolescent; Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Confidence Intervals; Cost-Benefit Analysis; Dipyridamole; Double-Blind Method; Drug Combinations; Female; France; Humans; Male; Middle Aged; Monte Carlo Method; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke | 2004 |
[Asasantin Retard or Persantin Retard+ASA?].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Stroke | 2004 |
[ASS plus dipyridamole instead of ASS monotherapy. Risk for second stroke cut in half].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Risk; Secondary Prevention | 2004 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Male; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticlopidine; United Kingdom | 2005 |
Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.
Topics: Algorithms; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Sample Size; Vascular Patency | 2005 |
[Germany's girths in an international comparison].
Topics: Abdominal Fat; Adult; Anthropometry; Aspirin; Aspirin, Dipyridamole Drug Combination; Body Mass Index; Cardiovascular Diseases; Cerebral Infarction; Combined Modality Therapy; Cross-Cultural Comparison; Dipyridamole; Drug Combinations; Female; Germany; Humans; Male; Practice Guidelines as Topic; Secondary Prevention; United Kingdom | 2005 |
[New DGN-/DSG guidelines].
Topics: Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic; Cross-Cultural Comparison; Dipyridamole; Drug Combinations; Germany; Humans; Ischemic Attack, Transient; Practice Guidelines as Topic; Societies, Medical; United Kingdom | 2005 |
Secondary stroke prevention and antiplatelet therapy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Stroke | 2006 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Endarterectomy, Carotid; Female; Hemorrhage; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pilot Projects; Platelet Aggregation Inhibitors; Postoperative Care; Randomized Controlled Trials as Topic; Research Design; Stroke; Ticlopidine; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2007 |
Improving depiction of benefits and harms: analyses of studies of well-known therapeutics and review of high-impact medical journals.
Topics: Antipsychotic Agents; Appetite Depressants; Aspirin; Aspirin, Dipyridamole Drug Combination; Contraceptives, Oral; Decision Making; Dipyridamole; Drug Combinations; Drug Evaluation; Evidence-Based Medicine; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Information Dissemination; Pharmacoepidemiology; Phenylpropanolamine; Review Literature as Topic; Risk Assessment; Stroke; Tissue Plasminogen Activator | 2007 |
Correction to the PRoFESS Trial paper by Diener et al. (Cerebrovasc Dis 2007;23:368-80.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Data Interpretation, Statistical; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Telmisartan; Ticlopidine | 2008 |
Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke | 2008 |
Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Female; Humans; Stevens-Johnson Syndrome | 2009 |
[Guidelines recommend aspirin/dipyridamole retard in high recurrence risk. Well protected from the second stroke].
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Ischemic Attack, Transient; Practice Guidelines as Topic; Secondary Prevention | 2009 |
A multi-case report of acute renal failure in patients treated with Aggrenox.
Topics: Acute Kidney Injury; Aspirin; Aspirin, Dipyridamole Drug Combination; Creatinine; Dipyridamole; Drug Combinations; Humans | 2010 |
Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention.
Topics: Aged; Algorithms; Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Confidence Intervals; Dipyridamole; Drug Combinations; Female; Fibrinolytic Agents; Humans; Male; Platelet Aggregation Inhibitors; Research Design; Sample Size; Stroke; Tissue Plasminogen Activator; Treatment Outcome | 2011 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Brain Ischemia; Clopidogrel; Cross-Sectional Studies; Dipyridamole; Drug Combinations; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stroke; Ticlopidine | 2013 |
Spray drying as a fast and simple technique for the preparation of extended release dipyridamole (DYP) microparticles in a fixed dose combination (FDC) product with aspirin.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Microscopy, Electron, Scanning; Particle Size; Solubility; Technology, Pharmaceutical; X-Ray Diffraction | 2014 |
Syncope during a pharmacologic nuclear stress test.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug Interactions; Exercise Test; Female; Heart Arrest; Humans; Middle Aged; Platelet Aggregation Inhibitors; Radiopharmaceuticals; Syncope | 2014 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Elective Surgical Procedures; Enoxaparin; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Prostate; Prostatic Hyperplasia; Retrospective Studies; Thromboembolism; Ticlopidine; Transurethral Resection of Prostate; Victoria; Warfarin; Withholding Treatment | 2015 |
Preventing arteriovenous shunt failure in hemodialysis patients: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Vessel Prosthesis Implantation; Clopidogrel; Databases, Factual; Female; Gastrointestinal Hemorrhage; Graft Occlusion, Vascular; Humans; Intracranial Hemorrhages; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation Inhibitors; Protective Factors; Renal Dialysis; Retrospective Studies; Risk Assessment; Risk Factors; Taiwan; Thrombosis; Treatment Failure; Warfarin; Young Adult | 2019 |